Skip Navigation


European Heart Journal Advance Access originally published online on December 17, 2004
European Heart Journal 2005 26(5):481-488; doi:10.1093/eurheartj/ehi073
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/5/481    most recent
ehi073v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (22)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Banfi, C.
Right arrow Articles by Agostoni, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banfi, C.
Right arrow Articles by Agostoni, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The European Society of Cardiology 2005. All rights reserved. For Permissions, please e-mail: journals.permissions{at}oupjournals.org

Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure

Cristina Banfi1,2,*, Viviana Cavalca2,3, Fabrizio Veglia2, Maura Brioschi1,2, Simona Barcella1, Luciana Mussoni1, Loredana Boccotti3, Elena Tremoli1,2, Paolo Biglioli2,3 and PierGiuseppe Agostoni2,3

1Department of Pharmacological Sciences, University of Milan, Via Balzaretti 9, 20133 Milan, Italy
2Centro Cardiologico Monzino, IRCCS, Milan, Italy
3Institute of Cardiology, University of Milan, Milan, Italy

Received 18 May 2004; revised 4 November 2004; accepted 15 November 2004; online publish-ahead-of-print 17 December 2004.

* Corresponding author. Tel: +39 0250318357; fax: +39 0250318250. E-mail address: cristina.banfi{at}unimi.it

Aims Development of heart failure depends on systemic and molecular abnormalities among which are the activation of neurohormonal systems and the increase of matrix metalloproteinases (MMPs). This study assessed the relationship between catecholamines and active MMPs in vivo in patients with severe congestive heart failure (CHF) and in vitro in human cardiac fibroblasts.

Methods and results Forty patients with CHF due to dilated cardiomyopathy, either idiopathic (n=20) or secondary to ischaemic heart disease (n=20), were compared with 20 healthy subjects. Plasma MMP-2 and MMP-9 activity, but not TIMP-2, were significantly higher in patients than in controls (median MMP-2, 270 vs. 214 ng/mL, P=0.006; MMP-9 16.3 vs. 8.7 ng/mL, P<0.0001). Similarly, noradrenaline, but not adrenaline, was significantly higher in patients (noradrenaline 645 vs. 157 pg/mL, P<0.0001; adrenaline 86.0 vs. 72.6 pg/mL, P=0.68). No difference in any parameter was observed between patient groups. The intra-group correlation between MMP-2 and noradrenaline was significant (r=0.33, P=0.01); indeed, noradrenaline appear to be a predictor of MMP-2. Moreover, this catecholamine increased MMP-2 in human cardiac fibroblasts.

Conclusions The positive correlation between noradrenaline and MMP-2 in severe CHF patients, together with the in vitro induction of MMP-2 by this catecholamine, suggests a potential biochemical link between noradrenaline and MMP-2.

Key Words: Metalloproteinases • Heart failure • Catecholamines • Noradrenaline


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Circ Heart FailHome page
A. Biolo, M. Fisch, J. Balog, T. Chao, P. C. Schulze, H. Ooi, D. Siwik, and W. S. Colucci
Episodes of Acute Heart Failure Syndrome Are Associated With Increased Levels of Troponin and Extracellular Matrix Markers
Circ Heart Fail, January 1, 2010; 3(1): 44 - 50.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
D. Poldermans, S. E. Hoeks, and H. H. Feringa
Pre-Operative Risk Assessment and Risk Reduction Before Surgery
J. Am. Coll. Cardiol., May 20, 2008; 51(20): 1913 - 1924.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
S. Frantz, S. Stork, K. Michels, M. Eigenthaler, G. Ertl, J. Bauersachs, and C.E. Angermann
Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: An independent predictor of mortality
Eur J Heart Fail, April 1, 2008; 10(4): 388 - 395.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
G. Laurent, G. Moe, X. Hu, H. Leong-Poi, K. A. Connelly, P. P.-S. So, A. Ramadeen, L. Doumanovskaia, A. Konig, J. Trogadis, et al.
Experimental studies of atrial fibrillation: a comparison of two pacing models
Am J Physiol Heart Circ Physiol, March 1, 2008; 294(3): H1206 - H1215.
[Abstract] [Full Text] [PDF]

Home page
 Eur J Heart FailHome page
A. T. Yan, R. T. Yan, F. G. Spinale, R. Afzal, H. R. Gunasinghe, R. E. Stroud, R. S. McKelvie, and P. P. Liu
Relationships between plasma levels of matrix metalloproteinases and neurohormonal profile in patients with heart failure
Eur J Heart Fail, February 1, 2008; 10(2): 125 - 128.
[Abstract] [Full Text] [PDF]

Home page
 Eur Heart JHome page
A. G.G. Turpie
New oral anticoagulants in atrial fibrillation
Eur. Heart J., January 2, 2008; 29(2): 155 - 165.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
G. Laurent, G. Moe, X. Hu, B. Holub, H. Leong-Poi, J. Trogadis, K. Connelly, D. Courtman, B. H. Strauss, and P. Dorian
Long chain n-3 polyunsaturated fatty acids reduce atrial vulnerability in a novel canine pacing model
Cardiovasc Res, January 1, 2008; 77(1): 89 - 97.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
A. G.G. Turpie
Oral, Direct Factor Xa Inhibitors in Development for the Prevention and Treatment of Thromboembolic Diseases
Arterioscler Thromb Vasc Biol, June 1, 2007; 27(6): 1238 - 1247.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.